These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6127066)

  • 21. Decreased dopamine and homovanillic acid excretion in a case with chlorpromazine-induced Parkinsonism.
    Messiha FS; Turek I
    Res Commun Chem Pathol Pharmacol; 1973 Jul; 6(1):329-30. PubMed ID: 4734007
    [No Abstract]   [Full Text] [Related]  

  • 22. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study.
    Avorn J; Bohn RL; Mogun H; Gurwitz JH; Monane M; Everitt D; Walker A
    Am J Med; 1995 Jul; 99(1):48-54. PubMed ID: 7598142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between structure and drug-induced parkinsonism.
    Sawada Y; Nasu R; Matsuo H; Ohtani H
    Ann Pharmacother; 2000 May; 34(5):668. PubMed ID: 10852100
    [No Abstract]   [Full Text] [Related]  

  • 24. Caudate hyperintensities in elderly depressed patients with neuroleptic-induced parkinsonism.
    Figiel GS; Krishnan KR; Doraiswamy PM; Nemeroff CB
    J Geriatr Psychiatry Neurol; 1991; 4(2):86-9. PubMed ID: 1677248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Permanent non-progressive cinnarizine and flunarizine-induced parkinsonism: An under-recognized tardive syndrome in the elderly?
    Calzetti S; Negrotti A
    J Neurol Sci; 2023 Jan; 444():120526. PubMed ID: 36584558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug-induced Parkinson`s disease. A clinical review.
    Bohlega SA; Al-Foghom NB
    Neurosciences (Riyadh); 2013 Jul; 18(3):215-21. PubMed ID: 23887211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of hyposmia and other non-motor symptoms to distinguish between drug-induced parkinsonism and Parkinson's disease.
    Morley JF; Duda JE
    J Parkinsons Dis; 2014; 4(2):169-73. PubMed ID: 24284418
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of the nitric oxide generation system in neuroleptic-induced Parkinsonism.
    Dolgo-Saburov VB; Dagaev SG; Kubarskaya LG; Solovjeva NE
    Dokl Biol Sci; 2012; 444():144-6. PubMed ID: 22760610
    [No Abstract]   [Full Text] [Related]  

  • 29. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
    Bitton V; Melamed E
    J Clin Psychiatry; 1984 Jan; 45(1):28-30. PubMed ID: 6141157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Is the glabellar reflex a component of neuroleptic-induced Parkinsonism?].
    Sánchez R; Calvo JM; Jaramillo LE
    Biomedica; 2005 Dec; 25(4):539-46. PubMed ID: 16433181
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A study of the early signs of drug induced parkinsonism.
    Arblaster LA; Lakie M; Mutch WJ; Semple M
    J Neurol Neurosurg Psychiatry; 1993 Mar; 56(3):301-3. PubMed ID: 8096240
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Motor and non-motor features of Parkinson's disease that predict persistent drug-induced Parkinsonism.
    Morley JF; Pawlowski SM; Kesari A; Maina I; Pantelyat A; Duda JE
    Parkinsonism Relat Disord; 2014 Jul; 20(7):738-42. PubMed ID: 24742370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Parkinsonism following neuroleptic exposure: A double-hit hypothesis?
    Erro R; Bhatia KP; Tinazzi M
    Mov Disord; 2015 May; 30(6):780-5. PubMed ID: 25801826
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and time trends of drug-induced parkinsonism: A 30-year population-based study.
    Savica R; Grossardt BR; Bower JH; Ahlskog JE; Mielke MM; Rocca WA
    Mov Disord; 2017 Feb; 32(2):227-234. PubMed ID: 27779780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroleptic-induced tardive dyskinesia and parkinsonism: changes during several years of continuing treatment.
    Casey DE; Povlsen UJ; Meidahl B; Gerlach J
    Psychopharmacol Bull; 1986; 22(1):250-3. PubMed ID: 2873612
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug-induced parkinsonism.
    Lancet; 1985 Jan; 1(8420):113. PubMed ID: 2857014
    [No Abstract]   [Full Text] [Related]  

  • 37. Drug-induced parkinsonism: relationship to age at onset of schizophrenia.
    Sandyk R; Kay SR
    Funct Neurol; 1991; 6(2):151-7. PubMed ID: 1680777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
    Tada M; Shirakawa K; Matsuoka N; Mutoh S
    Psychopharmacology (Berl); 2004 Oct; 176(1):94-100. PubMed ID: 15083255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinsonism by haloperidol and piribedil.
    Corsini GU; Del Zompo M; Spissu A; Mangoni A; Gessa GL
    Psychopharmacology (Berl); 1978 Oct; 59(2):139-41. PubMed ID: 103114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurologic approach to drug-induced movement disorders: a study of 125 patients.
    Miller LG; Jankovic J
    South Med J; 1990 May; 83(5):525-32. PubMed ID: 1971459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.